Constipation Therapeutics - Pipeline Review 2017, Patents, Designations and Developments

The study analyzed that the constipation therapeutics pipeline comprises approximately 18 drug candidates in different stages of development. Most of the drugs in pipeline for the treatment of constipation are in late stage of development. Constipation is a common functional gastrointestinal (GI) disorder that is most prevalent in the elderly and female population. According to the journal Clinical Interventions in Aging, published in 2015, the prevalence of the disease is around 20% in the world population, varying between 2% and 27% in different countries. The economic impact of chronic constipation is significant in the U.S., with around 100,000 constipation-related hospitalizations annually.


Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/constipation-therapeutics-pipeline-analysis/report-sample

Pharmaceutical companies are developing various drug candidates for the treatment of constipation in different stages of development including Filed, Phase III, Phase II, Phase I, and Pre-clinical. Albireo Pharma Inc. is in the process of developing a drug candidate, which is in the Filed stage of development, for treating constipation. There are small molecules as well as peptide type drug candidates in development for the treatment of constipation. A majority of the constipation therapeutics pipeline drugs are being developed as an oral dosage form.

With advances in technology, many pharmaceutical companies are leveraging new and improved technologies for the development of drug candidates to treat constipation. These technologies are helpful in the development of drugs as either combination therapies or single-agent therapies. They also allow development of specific targeted therapies with better drug delivery. For instance, Ardelyx Inc. has developed a unique platform that enables to discover targets in the GI tract, which control health and disease processes to optimize drug candidates and to understand their mechanisms of action.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=constipation-therapeutics-pipeline-analysis

Some of the players involved in the development of drug candidates for the treatment of constipation are Nordic Life Science Pipeline Inc., Enterin Inc., and Yuhan Corporation Ltd.

Prostatitis Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results and Development

The study analyzed that the prostatitis therapeutics pipeline comprises 11 drug candidates in different stages of development. Prostatitis is an infection or inflammation of the prostate gland that can lead to various syndromes with varying clinical features. The term prostatitis is defined as microscopic inflammation of the tissue of the prostate gland and it occurs due to a broad range of clinical conditions. The National Institutes of Health (NIH) has recognized and defined a classification system for prostatitis in 1999.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/prostatitis-therapeutics-pipeline/report-sample

The drug candidates of prostatitis pipeline are in different stages of development. Among them, majority of drugs are being developed to be administered by oral route. For instance, Prulifloxacin, a Phase II drug candidate by Angelini Acraf SpA, is being developed to be administered by oral route. Oral route increases the patient compliance as it does not require the assistance of other healthcare professionals. It is the prodrug of ulifloxacin a broad-spectrum fluoroquinolone antibacterial agent that blocks the type II DNA topoisomerase.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=prostatitis-therapeutics-pipeline

Some of the key players developing drugs for the treatment of prostatitis therapeutics include Angelini Acraf SpA, TFPHARMA, and Aquinox Pharmaceuticals, Inc.

Prostatitis Therapeutics Pipeline Analysis

• ·     By Phase
• ·     By Molecule Type
• ·     By Route of Administration
•      By Company

Cushing’s Syndrome Therapeutics - Pipeline Analysis 2017

The study analyzed that the Cushing’s syndrometherapeutics pipeline comprises of approximately 13 drug candidates.

Orphan drug designations from the European Medicines Agency (EMA) is the one of the drivers for the development of pipeline drugs of Cushing’s syndrome. Majority of the pipeline drug candidates are being developed using the oral route of administration. Osilodrostat which is being developed by the Novartis AG is in the Phase III stage of development for the treatment of Cushing’s syndrome.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cushing-syndrome-therapeutics-pipeline-analysis/report-sample

The existing drugs that are developed by the various pharmaceutical companies for the treatment of the disease have demonstrated positive clinical trial results, which in-turn is supporting their further development. For instance, Osilodrostat which is being developed by the Novartis AG demonstrated efficacy and well tolerated in the Phase II proof of concept study for the treatment of the Cushing’s syndrome.

The drug development process involves specific target such as steroid 11-beta-hydroxylase, which is the probable mechanism of action for the treatment of Cushing’s syndrome. Thus, this specific targeted therapy provides opportunities to the companies for better and targeted drug development. Some of the players developing drugs for the treatment of Cushing’s syndrome include Novartis AG, AstraZeneca Plc, Cyclacel Pharmaceuticals, Inc., and Angion Biomedica Corp.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=cushing-syndrome-therapeutics-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-Free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

Myasthenia Gravis Therapeutics – Designation, Collaboration, and Other Developments

The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development. Myasthenia gravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease worsens after a period of activity and improves after a period of rest.

Get Report Sample at @ http://bit.ly/2DI4cgu

Various companies, educational institutes and medical organizations are collaborating for the development of drugs for the treatment of this disease. For instance, Merck & Co., Inc. entered into a multi-targeted collaboration and license agreement with Ra Pharmaceuticals, Inc. to use the latter’s drug discovery technology platform for the development of orally available cyclic peptides for the treatment of myasthenia gravis.

It has been observed that most of the drugs in the myasthenia gravis therapeutics pipeline, are being developed from the natural source. NT-1654 is a heparan sulfate proteoglycan, and is under development by Neurotune AG for the treatment of myasthenia gravis. The drug acts as a neuromuscular junction stimulator.

Pre-Purchase Inquiry at: http://bit.ly/2DVbxN2

Some of the key players developing drugs for the treatment of myasthenia gravis include Alexion Pharmaceuticals, Inc., CSL Behring LLC, Novartis AG and others.

Japanese Encephalitis Therapeutics - Designations, Collaborations, and Developments

Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.

Shandong Hengye Biotech Co., Ltd., and VABIOTECH, have one drug candidates each in the Phase III stage of development for the treatment of the disease. The clinical studies of the vaccine, Vero cell-derived inactivated, is currently going on in China in the Phase III stage of development for the treatment of Japanese encephalitis.

Explore Report Sample at: http://bit.ly/2BB9Qiw

The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development. Based on molecule type, around 75.0% of the therapeutic candidates are being developed as vaccines, around 13.0% are made as peptide and 12.0% are being developed as small molecule.

In September 2017, VABIOTECH in collaboration with National Institute of Hygiene and Epidemiology (NIHE), Vietnam, initiated a Phase III, randomized, multi-centered, parallel groups assignment trial to assess the immunogenicity and safety of the JECEVAX in healthy male as well as female children of age between nine to 24 months.

Pre-Purchase Inquiry at: http://bit.ly/2DJ4Ji8

Some of the key players developing drugs for the treatment of Japanese encephalitis include Shandong Hengye Biotech, Co. Ltd., Panacea Biotec Ltd., and Ennaid Therapeutics, LLC.

Hyperhidrosis Therapeutics - Clinical Trials & Results, Designations and Collaborations

The study analyzed that the hyperhidrosis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.

Allergan Plc, TheraVida Inc., and GlaxoSmithKline Plc have one drug candidate each in the Phase II development for the treatment of hyperhidrosis. Glycopyrronium tosylate is the only drug candidate that has the Phase III stage of development for the treatment of hyperhidrosis. Majority of the pipeline drug candidates are being developed using the topical route of administration.

Get Report Sample at: https://www.psmarketresearch.com/market-analysis/hyperhidrosis-therapeutics-pipeline-analysis/report-sample

Major players in the market are putting more emphasis on targeting cholinergic receptors. The drug candidates used for the treatment of hyperhidrosis, act on cholinergic receptors and block its activity that interfere with sweating. For instance, Glycopyrronium tosylate, a Phase III drug candidate by Dermira, Inc. acts topically and blocks the cholinergic receptor.

In March 2015, Kaken Pharmaceutical Co., Ltd. and Brickell Biotech, Inc. entered in an agreement concerning the exclusive licensing and joint development of BBI-4000. Under the terms of agreement Brickell Biotech, Inc. agreed to conduct a Phase IIb clinical trial of BBI-4000 in the U.S. for patients with primary focal hyperhidrosis.

Pre-Purchas inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=hyperhidrosis-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of hyperhidrosis include Dermira, Inc., Allergan plc, TheraVida Inc. and others.

Browse Other Pharmaceuticals Research Report: http://bit.ly/2qP2pmt

Blood Collection Market - Global Industry Analysis, Size and Growth, 2023

The global blood collection market is witnessing considerable growth due to increasing geriatric population, increasing number of accidental cases and growing surgical procedures. Moreover, growing prevalence of chronic diseases including cancer, cardiovascular disease, infectious diseases, autoimmune diseases, diabetes mellitus, and infectious diseases is supporting the growth of the market. Based on product type, the blood collection needle and syringe segment lead the market. The increasing demand of needle and syringe for blood collection across the globe, owing to their easy availability and ease of use, is driving the growth of this segment. In addition, rising initiatives undertaken by government associations to boost awareness about blood donations and advanced features of blood collection products are also supporting to the growth of this market.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/blood-collection-market/report-sample

The use of RFID technology in blood banks and transfusion medicine has the potential to improve operational efficiency. It helps in providing patient safety at point of care by automatically identifying, reconciling, and tracking blood products throughout the blood supply chain. The increasing use of radiofrequency identification (RFID) and needle free devices is expected to create opportunities for the manufacturers of blood collection products. However, risk associated with blood transfusions and growing needlestick injuries are the key factors hampering the growth of the global market.

Request For Table of Content at: https://www.psmarketresearch.com/market-analysis/blood-collection-market/toc-sample

The key players operating in the global blood collection market are Abbott Laboratories Inc., Becton, Dickinson and Company, Terumo Corporation, Sarstedt AG & Co., Nipro Medical Corporation, Qiagen, Haemonetics Corporation, Greiner Holding AG and F.L. Medical SRL.

Topical Drug Delivery Market - Global Industry Analysis, Growth and Demand, 2023

Drugs that are applied to a local area on the body are known as topical drugs. Many creams and balms that are used for skin treatment are frequently called topical drug. Topical drug delivery market offers an alternative drug delivery system to treat many diseases and related conditions such as psoriasis, ringworm, rashes & blisters and others. The topical drug delivery has turned out to be progressively essential in the pharmaceutical industry. Eye drops and drugs utilized for inward breath in respiratory conditions such as asthma are also frequently known as topical medications. Topical medications have a local effect that means the effect of the drug will be only in the area where the drug has been applied; however, some topical medications can also have a systemic effect.

Explore Report at: https://www.psmarketresearch.com/market-analysis/topical-drug-delivery-market

The global topical drug delivery market is segmented on the basis of the product type, route of administration, indication for which the drug is used and its end users. Based on product type the market is segmented into formulations and devices, formulations are further sub-segmented into solid, liquid and semi-solid formulations, and devices. Semi-solid formulations include ointment, cream, gel lotion and paste and had a major contribution in the global topical drug delivery market in 2016, as compared to other sub-segments. The major factors driving the growth of semi-solid formulations include increasing rate of blood donations and rise in the number of surgical procedures such as organ transplantation where these formulations are widely used.

There are various factors that drive the growth of the topical drug delivery market including the increasing prevalence of dermal diseases, development of high technology in topical drug delivery systems, high number of cases of burn injuries, and increasing prevalence of diabetes, globally. According to the World Health Organization (WHO), the prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014, globally. Also, the WHO estimates that, diabetes would be the seventh leading cause of death, by 2030.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/topical-drug-delivery-market/report-sample

Some of the other key players operating in the global topical drug delivery market include Crescita Therapeutics Inc., SOLVAY S.A., Bayer AG, Cipla Limited, Galderma S.A, GlaxoSmithKline PLC, Janssen Global Services, LLC. (Johnson and Johnson), Novartis International AG, Sienna Biopharmaceuticals, Inc., Allergan PLC.

Asia-Pacific Scar Treatment Market Trends, Size, Growth and Demand till 2023

The Asia-Pacific scar treatment market size was valued at $3.6 billion in 2016, which is forecasted to reach $7.8 billion by 2023, growing at a CAGR of 11.6% during the 2017-2023. Among the various types of scar treatments, topical scar treatment is expected to lead the scar treatment market in the region, followed by surface, laser, injectable, and invasive surgical treatment.  Increasing focus on personal well-being, rising awareness about scar treatments and growing availability of non-invasive and less expensive topical scar treatment products are expected to be the drive the demand for topical scar treatment products.

Explore Report at: https://www.psmarketresearch.com/market-analysis/asia-pacific-scar-treatment-market

Hospitals were the largest end user in the regional market, mainly due to increasing healthcare expenditures by government and improving healthcare infrastructure. The other end users in the include private clinics, pharmacies & drug stores and e-commerce websites.

The Asia-Pacific scar treatment market is expected to grow at a faster rate as compared to other regions, due to increasing focus of general population on personal well-being, rising disposable income and growing prevalence of skin related problems such as burns, wounds and increasing number of cosmetic procedures performed in the region. According to the WHO, approximately 1,000,000 people suffer from moderate or severe burns, every year. These burn cases may lead to scar formation, leading to increased demand for scar treatment products in the region. According to the International Society of Aesthetic Plastic Surgery (ISAPS), the cosmetic surgeries performed in countries such as South Korea and India, are increasing at a rapid rate. In 2015, total surgical procedures performed in South Korea was 445,144, and in India, the number stood at 420,454.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/asia-pacific-scar-treatment-market/report-sample

The key players operating in the Asia-Pacific scar treatment market include Shanghai Fosun Pharmaceutical (Group) Company Limited, Beijing Toplaser Technology Company Limited, Sirnaomics, Inc., Essex Bio-Technology Limited, A. Menarini Asia-Pacific Holdings Pte. Ltd, Shiseido Company Limited, Concord Medisys Pvt. Ltd, Seoulin Bioscience Co. Ltd., Hanson Medical Inc., Otsuka Pharmaceutical Co., Ltd.

Latin America Scar Treatment Market - Global Regional Analysis, Top Manufacturers, Demand till 2023

The Latin America scar treatment market size was valued at $677.2 million in 2016, which is expected to attain $1,225.0 billion by 2023, growing at a CAGR of 8.9% during the forecast period (2017-2023). Topical scar treatment held the largest share of the market in 2016, ahead of surface, laser, injectable, and invasive surgical treatments. Scar treatment for keloid & hypertrophic scar is expected to witness the highest growth during forecast period in the regional market mainly due to increasing number of dermal injuries in the region.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/latin-america-scar-treatment-market/report-sample

Hospitals were the largest end user in the scar treatment market in Latin America and are expected to witness the highest growth, as compared to the private clinics, pharmacies & drug stores, and e-commerce in Latin America scar treatment market.

The demand for scar treatment in Latin America has been growing, mainly due to increasing awareness and consciousness about appearance among people in the region. The growth in the region is expected to be concentrated around Brazil, due to increasing demand of scar treatment products in the country. Additionally, the disposable income in Brazil has been increasing, due to which the affordability for such procedures has also increased. It has been also observed that the number of aesthetic plastic surgeries performed in the country for various purposes, including scar treatment has also been increasing. According to the International Society of Aesthetic Plastic Surgery (ISAPS), 461,544 cosmetic surgeries were performed in Mexico in 2016, the third highest in the world after the U.S. and Brazil and 907,913 non-surgical procedures were performed in Mexico, the fourth highest in the world after the U.S., India and Brazil, thus driving the growth of the Latin America market.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=latin-america-scar-treatment-market

The key players are focusing on gel based scar treatment in the Latin America market. For instance, Medgel is an advanced line of silicone gel, offered by Silimed Inc., for treatment or prevention of scars, hypertrophic scars and keloid. Similarly, GC Aesthetics, recently launched Silgel direct to the consumers for the first time. Silgel is a silicone gel based, product for the treatment of hypertrophic and keloidal scars.

Some of the key players operating in the Latin America scar treatment market include Advanced Biotechnologies Inc., Scar Heal Inc., Silimed Inc., Natura Cosméticos S.A., Grupo Biomayan, Biodermis Cosmetics Ltd., GC Aesthetics PLC, Humco Holding Group, Inc., Farmoquimica S.A.

Europe Sleeping Aids Market Analysis, Size, Growth and Demand, 2022

The European sleeping aids market was valued at $14.8 billion in 2015 and is forecasted to grow at a CAGR of 6.2% during 2016-2022. Various sleep disorders are hampering the lives of people in the region, due to increasing tobacco and alcohol consumption, rising aging population, growing population base working in night shifts and changing lifestyle habits of the Europeans. Sleep disorders such as insomnia, sleep apnea, restless legs syndrome, narcolepsy, sleep walking and others greatly affect the population base in the European region.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/europe-sleeping-aids-market/report-sample

Sleeping aids namely mattress & pillow, sleep laboratories, medication, sleep apnea devices and others are largely used for the above-mentioned sleeping disorders. Mattress & pillows held the largest share in the European sleeping aids market and contributed 43% in 2015. Amongst all the sleep related problems people are being majorly affected by insomnia and sleep apnea in the Europe.

Increasing awareness about sleep disorders and risks associated with them, by various organizations such as the British Sleep Society and Survey Sleep Research Center has been driving the demand of the sleeping aids products in the region. According to the Eurostat, aging population is a long-term trend in the region, this is also a key factor driving the demand for sleeping aids in the region. The share of population aged 65 years and over is increasing in every European Union (EU) member state. During the period 2016 to 2080 the aging population is expected to account for a share of 29.1% of the EU-28 population compared to 19.2% in 2016.

Explore Report at: https://www.psmarketresearch.com/market-analysis/europe-sleeping-aids-market

Some of the key players operating in the European sleeping aids industry are Sanofi S.A., Koninklijke Philips N.V., GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer Inc., Roche Holding AG, AstraZeneca plc, Becton, Dickinson and Company, Drive Medical Ltd., Somnomedics Gmbh and Cardinal Health.

Cleanroom Technology Market - Global Industry Trends, Analysis and Demand, 2023

Cleanroom technology market is forecasted to attain $5 billion value by 2023, growing at a CAGR of 5.7% during 2017-2023. The growth in the market is likely to be led by increased demand for certified products, rising healthcare expenditure, technological advancements in cleanrooms, rising demand from pharmaceutical, biotech, and medical devices industries, and favorable healthcare regulations.

Explore Report Sample at @ http://bit.ly/2x2XXka

In terms of technology type, the cleanroom technology market has been categorized as equipment and consumables, where consumables occupied a larger share in the global market in 2016. Consumables are cheaper and do not involve any installation and maintenance cost, as compared to the equipment used in cleanrooms. The equipment used in cleanroom technology industry include heating, ventilating, and air conditioning (HVAC) systems, high-efficiency particulate air (HEPA) filters, fan filter units (FFUs), laminar air flow systems and biosafety cabinets, air diffusers and showers, and other equipment, among these the HVAC systems held the largest share in the market, in 2016.

Cleanroom technology products are mainly used in the pharmaceutical, biotechnology, and medical devices industries, with some of the other users being hospitals, research laboratories and academic institutions. Pharmaceutical industry contributed the largest share to the cleanroom technology market and its growth is mainly attributable to the presence of a large number of biopharmaceutical companies, which further leads to a high production of finished pharmaceutical products, worldwide.

Pre-Purchase Inquiry at @ http://bit.ly/2CTc56z

Globally, the key providers in the cleanroom technology market are launching new products to gain a larger market share. For instance, in September 2016, Clean Air Products Inc., a designing and manufacturing company for cleanroom systems, announced the launch of new touchscreen interface for its air showers - model CAP701KD-ST. The enhanced feature enables easier control of the cycle timings and program changes of its air showers. The HMI interface displays a visual instruction of where the air shower is in the cycle and also includes a countdown screen that informs occupants about the time remaining in the air shower.

Some of the other key players operating in the cleanroom technology market include M+W Group GmbH, E.I. du Pont de Nemours and Company, Kimberly-Clark Corporation, Taikisha Ltd., Azbil Corporation, Illinois Tool Works Inc., Ardmac Ltd., and Alpiq Group.

Endometrial Cancer Therapeutics Market - Epidemiology Analysis, Size and Growth, 2023

Global endometrial cancer therapeutics market is expected to witness significant growth as there are less number of approved drugs for treatment of endometrial cancer, leading to an increased opportunity for the drug manufacturers. High prevalence of cancer and rising demand for safe and effective medications can be attributed as the major drivers of this market. The regulatory bodies such as USFDA and EMA are supporting the growth of the global market by providing increased funding, designations and grants for speeding up the drug development process.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market/report-sample

Endometrial cancer is the malignancy that develops in the layers of the cells that forms endometrium, lining of uterus. The precise cause of endometrial cancer is still unknown but it is assumed that estrogen may be involved in developing endometrial cancer, as estrogen helps in the formation of the endometrial lining. Obesity, polycystic ovary syndrome, infrequent periods and history of endometrial polyps can increase the risk of endometrial cancer. Women with diabetes, high blood pressure or breast cancer are at a greater risk of having endometrial cancer. Abnormal vaginal bleeding, bleeding between periods or after menopause, lower abdominal cramps or clear vaginal discharge after menopause are some of the main symptoms of endometrial cancer.

Though, chemotherapy is projected to have the maximum share in the global endometrial cancer therapeutics market owing to high adoption rate of chemotherapy over surgical treatment and radiation therapy in oncology. Also, carboplatin and paclitaxel are recommended as chemotherapeutic agents for first line of therapy in majority of the cases, which increases demand for these products. FDA recently approved IXEMPRA (ixabepilone) for use in endometrial cancer treatment which is likely to increase the growth of market during in the future.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/endometrial-cancer-treatment-market/toc-sample

Geographically, North America is expected to be the largest market for endometrial cancer therapeutics treatment, owing to the large number of research and development activities ad high healthcare expenditure. Europe is expected to hold the second largest share in the global market owing to growing product availability in the region.

Some of the key players operating in the global endometrial cancer therapeutics market are AstraZeneca Plc., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc. and R-Pharm-US LLC.

Esophageal Cancer Therapeutics Market - Epidemiology Analysis, Growth and Demand, 2023

Global esophageal cancer therapeutics market is expected to witness significant growth with an increasing awareness regarding cancer treatment and technological advancements. Also, high demand for safe and effective medications and rising prevalence of cancer are driving the growth of the global market. The regulatory bodies such as USFDA, EMA are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process.

Esophageal cancer involves formation of malignant cells in the tissues of the esophagus. Esophagus is a muscular tube that enable food and liquids to move from the throat to the stomach. The main types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. Adenocarcinoma forms in cells that produce and release mucus and other fluids. Squamous cell carcinoma forms in flat cells lining the esophagus. Esophageal squamous cell carcinoma includes heavy alcohol consumption and smoking as major risk factors, with gastroesophageal reflux disease and Barrett esophagus further contributing as the risk factors of esophageal adenocarcinoma. Esophageal cancer has no early signs or symptoms; therefore, an advanced stage diagnosis is difficult.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/esophageal-cancer-therapeutics-market/report-sample

The marketed drugs for esophageal cancer treatment includes Ramucirumab (Cyramza), Docetaxel (Docefrez), and Trastuzumab (Herceptin) for adenocarcinoma. Also, XELIRI and FU-LV are combination drugs given along with the chemotherapy that contributes in the global esophageal cancer therapeutics market.

Genentech, Inc. markets Trastuzumab (Herceptin) in combination with cisplatin and a fluoropyrimidine (either capecitabine or 5-fluorouracil), for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarcinoma who were not treated for metastatic disease prior.

Certain chemotherapy medications such as Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Chlorambucil, Procarbazine Prednisolone, Mustine, Vincristine, Etoposide, Cyclophosphamide, Gemcitabine, Cisplatin and Cytarabine are well established as a conventional method. Immunotherapy, combination therapy, monoclonal antibodies and steroids have also been showing good results for the treatment of esophageal cancer.

Explore Report at: https://www.psmarketresearch.com/market-analysis/esophageal-cancer-therapeutics-market

Some of the key players operating in the global esophageal cancer therapeutics market include Genentech, Inc., Sanofi-Aventis, Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., Merck & Co., Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, Gilead Sciences, and Bristol-Myers Squibb, among others.

Neuroendocrine Carcinoma Therapeutics Market - Global Industry Analysis, Growth and Demand, 2023

Global neuroendocrine carcinoma therapeutics market is witnessing significant growth due to large number of marketed drugs and Phase III drugs. Neuroendocrine carcinoma is a tumor that begins in neuroendocrine cells and can spread, or metastasize, to other parts of the body. It starts in the hormone producing cells of the body’s neuroendocrine system. Neuroendocrine tumors can begin in many organs including, lungs, brain and gastrointestinal tract. It is a very rare cancer with symptoms such as hyperglycemia, hypoglycemia, diarrhea, weight loss, pain, cough, lump formation, jaundice, unusual bleeding, headache and anxiety. The risk factors of developing neuroendocrine cancer includes, age, gender, family history, immune system suppression, arsenic exposure and sun exposure. The diagnosis can be done by normal physical examination followed by blood tests, urine tests, X- ray, CT scan, PET scan, MRI and biopsy.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/neuroendocrine-carcinoma-therapeutics-market/report-sample

The treatments available for neuroendocrine tumor include chemotherapy, surgery and radiation therapy. Chemotherapy comprises the drug’s use to destroy malignant cells by hindering the cells ability to divide and grow. Streptozocin (Zanosar) and 5-fluorouracil (Adrucil, 5-FU) are some of the drugs that are used to treat neuroendocrine tumors. Many pharmaceutical companies have been working continuously for the development of targeted therapy for the growth of neuroendocrine cancer market.

Geographically, neuroendocrine carcinoma therapeutics market has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). According to Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer every year in the U.S. Several key players functioning in neuroendocrine carcinoma therapeutics market are based in the U.S and therefore consider North America as their main market for product launch and research and development investments. Also, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America’s neuroendocrine carcinoma therapeutics market. Europe is the second largest market for neuroendocrine carcinoma therapeutics, followed by Asia. Increasing prevalence of neuroendocrine cancer in Asia Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/neuroendocrine-carcinoma-therapeutics-market/toc-sample

Some of the key players operating in the global neuroendocrine carcinoma therapeutics market include Pfizer Ltd., Eli Lilly & Company, Novartis AG, F. Hoffmann-La Roche Ltd., Ispen SA, Amgen, Inc., Callisto Pharmaceuticals Pvt. Ltd., Biosynthema, Inc., Teva Pharmaceuticals, Ltd. and Bristol-Myers Squibb among others.